List of Excipients in Branded Drug DYRENIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Advanz Pharma (US) Corp	DYRENIUM	triamterene	59212-002	D&C RED NO. 33
Advanz Pharma (US) Corp	DYRENIUM	triamterene	59212-002	FD&C YELLOW NO. 6
Advanz Pharma (US) Corp	DYRENIUM	triamterene	59212-002	GELATIN
Advanz Pharma (US) Corp	DYRENIUM	triamterene	59212-002	LACTOSE

Dyrenium Excipient Strategy and Commercial Opportunities for Triamterene

Last updated: August 9, 2026

Dyrenium is the branded oral formulation of triamterene, a potassium-sparing diuretic used alone or with other diuretics to reduce potassium loss. Its commercial opportunity is no longer based on conventional composition-of-matter exclusivity. The strongest opportunities are reformulated triamterene products that improve swallowability, dosing convenience, excipient tolerability, combination therapy, and adherence while preserving bioequivalence and renal-safety controls.

What is Dyrenium and which formulation attributes matter commercially?

Dyrenium contains triamterene in 50 mg and 100 mg capsules. Triamterene is used for edema associated with congestive heart failure, cirrhosis of the liver, and nephrotic syndrome, and for edema caused by corticosteroids or hyperaldosteronism. It is also used with thiazide diuretics when potassium depletion is a clinical concern. [1]

Attribute	Dyrenium commercial relevance
Active ingredient	Triamterene
Pharmacologic class	Potassium-sparing diuretic
Dosage form	Oral capsule
Strengths	50 mg and 100 mg
Main therapeutic role	Potassium conservation and diuresis
Key safety issue	Hyperkalemia
Important patient groups	Older adults, patients with renal impairment, heart failure and hypertension
Primary formulation challenge	Low aqueous solubility and dependence on consistent oral exposure
Principal competitive products	Generic triamterene capsules and triamterene/hydrochlorothiazide combinations
Original regulatory position	Long-established small-molecule product with no meaningful modern composition-of-matter exclusivity

The label directs laboratory monitoring of serum potassium, particularly during initiation, dose changes, illness, or use of other potassium-raising medicines. [1] That safety profile makes formulation changes commercially useful only if they do not increase exposure variability or impair dose control.

What excipients are used in Dyrenium capsules?

The Dyrenium label identifies conventional capsule excipients, including lactose, magnesium stearate, sodium lauryl sulfate, gelatin, and colorants. Exact inactive-ingredient declarations can vary by strength, manufacturer, and label revision. [1,2]

Functional role of the principal excipients

Excipient category	Typical role in triamterene capsules	Commercial assessment
Lactose	Diluent and fill-volume adjustment	Low cost, but creates a lactose-intolerance and excipient-labeling issue
Magnesium stearate	Lubricant	Useful at low concentration; excessive levels can affect wetting and dissolution
Sodium lauryl sulfate	Surfactant and wetting aid	May support dissolution of a poorly water-soluble drug; requires tight control for gastrointestinal tolerability
Gelatin	Capsule shell	Familiar and inexpensive; not suitable for vegetarian, vegan or some religious-market positioning
Titanium dioxide and organic colorants	Capsule opacity and product identification	Useful for differentiation, but subject to regional regulatory and consumer scrutiny

The most commercially relevant point is that excipient selection affects triamterene dissolution. Triamterene has low aqueous solubility, so surfactant level, particle size, blend uniformity, capsule fill, and manufacturing conditions can influence release. A reformulation should be developed as a performance-controlled product, not as a simple excipient substitution.

How should a company design a new Dyrenium excipient platform?

A practical strategy is to separate products into three development tiers.

Tier 1: Low-risk generic capsule

The first product should preserve the capsule format and target the reference product's dissolution and pharmacokinetic profile. The formulation can replace or reduce selected excipients while maintaining the same dose strengths.

Potential objectives include:

• Lactose-free formulation
• Reduced or alternative surfactant system
• Hypromellose capsule shell
• Improved colorant and imprinting system
• Lower capsule-fill variability
• Simplified manufacturing process
• Gluten-free and allergen-controlled positioning where supportable

This approach offers the shortest development path because the dosage form, route, strengths, and administration method remain familiar.

Tier 2: Patient-friendly capsule or multiparticulate product

A second platform could use a smaller capsule, coated granules, or multiparticulates. The commercial targets would be older patients, polypharmacy patients, and patients with dysphagia.

Potential formats include:

• Smaller capsule using higher-density granules
• Sprinkle product for administration with soft food
• Sachet or stick-pack containing coated pellets
• Capsule-in-capsule presentation
• Modified visual identification for medication-error reduction

A sprinkle product would require control of taste, gastric release, dose recovery from the food vehicle, and stability after opening. Uncoated triamterene particles may create bitterness or uneven dosing. A taste-masked multiparticulate system would have higher development cost but stronger differentiation.

Tier 3: Reformulated combination product

The largest commercial opportunity may be in triamterene combination therapy rather than Dyrenium monotherapy. Triamterene is commonly used with hydrochlorothiazide to offset potassium loss associated with thiazide treatment. Existing combination products include triamterene/hydrochlorothiazide products such as Dyazide and Maxzide. [3,4]

A new combination platform could focus on:

• Lower-dose triamterene with hydrochlorothiazide
• Multiple hydrochlorothiazide strengths
• Once-daily adherence
• Smaller tablet or capsule size
• Improved dissolution matching across both active ingredients
• Reduced tablet burden
• Packaging that separates strength variants clearly

Combination development is technically difficult because triamterene and hydrochlorothiazide have different solubility and formulation requirements. A single matrix may produce uneven release or manufacturing segregation. Bilayer, multilayer, coated-granule, or physically separated multiparticulate systems may provide better control.

What formulation patents could protect a new triamterene product?

A new triamterene product would likely obtain its strongest patent protection from formulation and manufacturing claims rather than from the active ingredient.

Potential patent claim categories

Patent category	Example claim focus	Commercial value
Solubility-enhanced formulation	Surfactant, amorphous dispersion, nanocrystal or lipid system	High if it produces a measurable exposure or dissolution advantage
Multiparticulate delivery	Coated pellets, taste-masked granules, sprinkle dosage form	High for pediatric, geriatric and dysphagia markets
Fixed-dose combination	Specific triamterene and hydrochlorothiazide architecture	Moderate to high, depending on differentiation
Manufacturing process	Granulation, drying, lubrication, capsule filling or coating parameters	Moderate; strongest when process controls are difficult to design around
Stability package	Moisture-protective capsule or packaging system	Moderate
Patient-use system	Opening, sprinkling, dose recovery or adherence packaging	Moderate, with enforcement dependent on claim scope
Method of use	Use in a defined patient population or dosing regimen	Variable and potentially limited by prior art

A patent should not rely only on the presence of a routine excipient. Claims directed to "triamterene plus lactose" or "triamterene plus magnesium stearate" would face substantial obviousness and enablement risk. The defensible claim should connect the excipient system to a measurable technical result, such as a dissolution profile, exposure range, stability period, reduced dose variability, or improved administration performance.

When does Dyrenium lose exclusivity and what is the Orange Book status?

Dyrenium is a legacy small-molecule product. Its original active-ingredient and basic formulation exclusivity expired decades ago. The product does not have the commercial profile of a recently approved branded drug with an active patent estate.

The FDA Orange Book should be checked for the current NDA, strength, and any listed patents or exclusivity codes before a filing or launch decision. [5] For a legacy product such as Dyrenium, the commercial barrier is generally regulatory execution and market access rather than an active branded patent blocking ordinary generic entry.

Exclusivity issue	Dyrenium assessment
New chemical entity exclusivity	Expired
Basic capsule formulation exclusivity	Expired or commercially exhausted
Pediatric exclusivity	No current strategic relevance identified
Orphan exclusivity	Not a principal product barrier
Orange Book patent risk	Low for the legacy product, subject to current listing verification
Generic pathway	Abbreviated New Drug Application likely for equivalent capsule products
Reformulation pathway	May require a new drug application or other regulatory route, depending on changes

Which companies are challenging Dyrenium and what is the Paragraph IV risk?

The principal competitive risk is not a new Paragraph IV campaign against the old Dyrenium capsule. It is substitution by approved generic triamterene capsules and triamterene/hydrochlorothiazide products.

For a new formulation, Paragraph IV risk would depend on whether the sponsor seeks approval by referencing a listed product with active patents. A generic applicant could challenge formulation or method-of-use patents through an ANDA Paragraph IV certification if those patents were listed against the reference product. [6]

A formulation owner should expect challenges to claims that cover:

• Routine capsule excipients
• Broad ranges of surfactant or lubricant
• Conventional granulation steps
• General food administration
• Undifferentiated patient populations

A stronger patent position would require narrow, experimentally supported claims tied to a distinct product profile.

How strong is the patent estate for a new Dyrenium formulation?

The patent estate for legacy Dyrenium is weak as a blocking estate. The opportunity is to create a new estate around a differentiated product.

Stronger patent positions

A new triamterene formulation has greater patent potential when it includes:

1. A defined particle-size distribution linked to dissolution performance.
2. A specific wetting or solubilization system.
3. A coated multiparticulate that prevents taste release in the mouth.
4. A validated sprinkle method with dose-recovery specifications.
5. A fixed-dose combination with controlled spatial separation of actives.
6. A stability advantage under accelerated humidity conditions.
7. A manufacturing sequence that consistently produces a non-obvious release profile.

Weaker patent positions

The following claims are more vulnerable:

• Generic lactose-free composition claims
• Simple replacement of gelatin with hypromellose
• Conventional capsule-color claims
• Broad excipient percentage ranges without technical data
• Routine changes to particle size or lubricant concentration
• Claims that merely restate the known use of triamterene for potassium conservation

The best strategy is a layered portfolio: composition claims, dosage-form claims, process claims, use claims, and packaging claims filed around a common technical platform.

What FDA regulatory pathway applies to Dyrenium reformulation?

An ordinary equivalent capsule may be developed through the ANDA pathway if it meets applicable requirements for sameness, bioequivalence, quality, labeling, and product performance. [6]

A materially different dosage form, sprinkle product, taste-masked system, or fixed-dose combination may require a different regulatory strategy. The pathway depends on the proposed reference product, active ingredients, formulation differences, clinical claims, and whether the product can rely on an established drug record.

Key regulatory workstreams include:

• Comparative dissolution under multiple pH conditions
• Fed and fasting pharmacokinetic assessment
• Dose proportionality for 50 mg and 100 mg strengths
• Impurity and degradation-product control
• Capsule-shell compatibility
• Moisture and oxygen stability
• Extractables and leachables for new packaging
• Dose recovery from food vehicles for sprinkle products
• Clinical or pharmacokinetic support for new combinations

Because hyperkalemia is a central safety risk, the sponsor should avoid a formulation that creates a higher peak concentration or greater exposure variability without a clear clinical rationale.

What commercial opportunities exist beyond the legacy Dyrenium capsule?

Lactose-free and vegetarian positioning

Replacing lactose and gelatin could broaden access for patients with excipient restrictions and support institutional formulary requirements. This is a modest opportunity unless paired with a clear supply, quality, or adherence benefit.

Dysphagia and geriatric delivery

A sprinkle capsule or coated-pellet product could address a defined patient need. The opportunity is stronger in long-term-care and home-health channels, where swallowing difficulty and medication burden are common.

Fixed-dose combination products

Triamterene/hydrochlorothiazide combinations have broader commercial relevance than triamterene monotherapy because they align with routine hypertension and edema management. A smaller, easier-to-administer combination could compete on adherence and dispensing efficiency.

Contract and institutional supply

A reliable, shortage-resistant product with stable manufacturing economics could attract hospital, long-term-care, and government purchasing. The active ingredient is inexpensive, so supply continuity, quality history, and contract pricing will determine adoption.

International markets

Geographic expansion should prioritize markets where triamterene remains clinically used and where combination products have limited availability. Regulatory filings must account for differences in capsule colorants, titanium dioxide policy, gelatin sourcing, lactose labeling, and bioequivalence requirements.

How does Dyrenium compare with triamterene/hydrochlorothiazide products?

Factor	Dyrenium monotherapy	Triamterene/hydrochlorothiazide combination
Primary value proposition	Potassium-sparing diuresis	Diuresis with reduced potassium loss
Formulation complexity	Moderate	High because of two active ingredients
Patient convenience	Lower when combined with a separate thiazide	Higher as a single product
Market size	Narrower	Broader hypertension and edema use
Excipient opportunity	Lactose-free, vegetarian, sprinkle and capsule optimization	Dose architecture, release control, size reduction and adherence
Patent opportunity	Formulation and delivery claims	Combination, architecture, process and method claims
Main clinical risk	Hyperkalemia	Hyperkalemia plus dose-balance issues
Commercial differentiation	Patient-friendly delivery	Fixed-dose convenience and strength flexibility

What generic launch scenarios exist for a new Dyrenium product?

A low-cost generic capsule would face immediate price competition and limited brand loyalty. A differentiated product could follow three launch scenarios.

Scenario	Product	Likely commercial outcome
Commodity launch	Standard 50 mg and 100 mg capsules	High substitution but low margins
Specialty generic	Lactose-free or vegetarian capsule	Moderate differentiation; payer support required
Value-added product	Sprinkle or multiparticulate capsule	Higher pricing potential, narrower eligible population
Combination platform	Triamterene/hydrochlorothiazide	Larger market, higher technical and regulatory burden

Revenue exposure to legacy Dyrenium is likely limited relative to large cardiovascular products. The business case depends on manufacturing cost, contract access, channel strategy, and the ability to secure differentiated reimbursement. A reformulation without a defensible clinical or operational benefit will probably be treated as another generic.

Key Takeaways

• Dyrenium is a legacy triamterene capsule with no meaningful modern composition-of-matter exclusivity.
• The main excipient opportunities are lactose removal, gelatin replacement, dissolution optimization, and improved capsule performance.
• The strongest commercial opportunity is likely a patient-friendly formulation or triamterene/hydrochlorothiazide combination.
• A new patent estate should claim measurable technical performance, not routine excipient substitutions.
• The most important development controls are dissolution, fed-state exposure, dose uniformity, stability, and renal-safety consistency.
• Generic competition is established; commercial success requires supply reliability, adherence value, or a differentiated dosage form.
• Current Orange Book listings and manufacturer-specific inactive ingredients must be checked before filing, licensing, or litigation decisions.

FAQs

Can Dyrenium be reformulated as a lactose-free product?

Yes. Lactose can potentially be replaced with alternative fillers such as microcrystalline cellulose, mannitol, or selected starch-based materials. The substitute must preserve capsule-fill properties, dissolution, stability, and bioequivalence.

Is a triamterene oral suspension commercially attractive?

It could serve patients unable to swallow capsules, but taste masking, chemical stability, dose uniformity, and preservative compatibility create substantial development requirements. A coated multiparticulate or sprinkle product may offer a better balance of usability and stability.

Can a new excipient combination qualify for patent protection?

Yes, if the combination produces a non-obvious and measurable result. A routine excipient substitution without improved dissolution, stability, bioavailability, or administration performance would have weaker patent prospects.

Are biosimilar risks relevant to Dyrenium?

No. Triamterene is a chemically synthesized small molecule, not a biologic. Competitive risk comes from generic ANDA products and reformulated small-molecule combinations, not biosimilars.

What is the highest-value commercial formulation for triamterene?

A smaller, patient-friendly fixed-dose triamterene/hydrochlorothiazide product with reliable dissolution, flexible strengths, and a defensible manufacturing or delivery patent has greater commercial potential than an undifferentiated Dyrenium capsule.

References

1. U.S. Food and Drug Administration. (n.d.). Dyrenium (triamterene) capsule prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: Dyrenium and triamterene capsule labeling.
3. U.S. Food and Drug Administration. (n.d.). Dyazide (hydrochlorothiazide and triamterene) prescribing information.
4. U.S. Food and Drug Administration. (n.d.). Maxzide (hydrochlorothiazide and triamterene) prescribing information.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
6. U.S. Food and Drug Administration. (n.d.). ANDA submissions: Content and format of an ANDA.